% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

  • dashaftfromgsk dashaftfromgsk Jun 25, 2013 10:30 AM Flag

    TLR-9 agonist cornerstone for dominating global vaccine market

    Yes, that's what we're talking about here. GSK have their own strategies and DVAX was/is still a threat. I'm thinking they don't want to get into a bidding war with anyone so they are trampling DVAX down in hopes of lowering perceived value to other BP. I am of the opinion that DVAX gets acquired before end of next year, and not necessarily by GSK. Think a bidding war could still happen, but we are going to need some traction here or in the EU. Happy trades!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Been looking for the reason Grey is not with GSK anymore.
      It would be a nice twist to find out he has a bone with them.
      And his new role is to keep GSK from acquiring Heplisav or make them pay up.

      • 2 Replies to outboard.jack
      • Contrary, I hope there is no bone and his job is to have GSK acquire. A possible US approval is now ~3 years out; no chance IMO we'd see even close to $5 again next several years, given dilution required to run a large trial. I'll GLADLY take $2-$2.50 from GSK and move on from this company that seemed to have alot going for it but proved a shipwreck.

      • In 2011, we initiated the first human clinical trial with DV1179 in healthy volunteers. DV1179 was shown to be well-tolerated in this Phase 1 trial, and, subsequently, in late 2011, we initiated a proof-of-mechanism clinical study of DV1179 in systemic lupus erythematosus (SLE) patients.

        Commercial Opportunity

        Over 20 million individuals in the U.S. and Europe have autoimmune diseases such as lupus, psoriasis, and rheumatoid arthritis. Key biologic drugs used to treat these conditions generate over $15 billion in worldwide sales each year.

15.850.00(0.00%)May 27 4:00 PMEDT